<DOC>
	<DOCNO>NCT01771549</DOCNO>
	<brief_summary>This pilot study involve frequent monitoring breast cancer patient blood level hs-cTnT Troponin n-t-BNP ( Brain Natriuretic Peptide ) initiation chemotherapy either adriamycin trastuzumab order define kinetics biomarkers first two cycle chemotherapy . Cardiac troponins BNP frequently elevate experimental chemotherapy animal model . Their behavior human inconsistent , occasional elevation see , usually within 30 day therapy . Assays troponin sensitivity pg/ml range introduce . A majority patient great age 50 elevation detection limit , compare 1-3 % conventional troponin assay , 90 % diabetic elevation detection limit . Moreover , augment release high sensitivity troponin detect exercise rapid atrial pacing duration 10-15 minute patient without coronary artery disease . This improved sensitivity suggest potential detection monitoring cardiac damage cancer chemotherapy . We hypothesize new generation troponin assay would associate kinetic behavior suggest ongoing cardiac damage anthracycline therapy , possibly also trastuzumab .</brief_summary>
	<brief_title>Kinetics Troponin BNP Breast Cancer Chemotherapy With Adriamycin Trastuzumab</brief_title>
	<detailed_description>Collect blood sample two group patient ( n=10 per group ) amino-terminal brain natriuretic peptide ( n-t-BNP ) high sensitivity cardiac troponin T ( hs-cTnT ) : - Group 1 ( adriamycin ) consist patient begin clinically indicate chemotherapy breast cancer dose-dense ( every 2 week ) regimen . include adriamycin ( n=10 ) . - Group 2 include patient receive trastuzumab adjuvant ( neo ) adjuvant setting , metatstatic set regimen include simultaneous adriamycin . Blood sample hs-cTNT n-t-BNP obtain day pre-treatment , post-treatment day 1 , 2 , 3 , 7 , pre-cycle 2 , post-cycle 2 day 1,2,3 7 . The interval treatment usually two week adriamycin three week trastuzumab . We identify frequency detectible level detection limit baseline , peak value area curve . Enrollment 15 per group allow guarantee acquisition 10 full set sample . Lab draw chemotherapy port allow . We plan store specimens future analyse sensitive assay development .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Female adult patient age 18+ Group 1 : beginning clinically indicate chemotherapy breast cancer dosedense ( every 2 week ) regimen include adriamycin ( n=10 ) . Group 2 : patient receive trastuzumab adjuvant , ( neo ) adjuvant , metastatic set regimen include simultaneous adriamycin . Inability return clinic regular phlebotomy Baseline hemoglobin &lt; 10 gm/dl Creatinine clearance &lt; 60 ml/minute ( effect troponin clearance ) Recent ( &lt; 3 month ) cardiac surgery , myocardial infarction , unstable angina , hospitalization congestive heart failure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Adriamycin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Brain Natriuretic Peptide ( BNP )</keyword>
	<keyword>Troponin</keyword>
</DOC>